<DOC>
	<DOCNO>NCT00831753</DOCNO>
	<brief_summary>The study aim confirm , Peruvian infant , investigational DTaP-IPV Hep B-PRP~T vaccine immunological safety profile comparable control vaccine already market ( Infanrix®Hexa ) Primary Objective : To demonstrate hexavalent DTaP-IPV-Hep B-PRP~T combine vaccine induces immune response least good response follow Infanrix®Hexa term seroprotection rate HB , one month three-dose primary series ( 2 , 4 6 month ) Secondary Objectives : - To describe group immunogenicity vaccine component ( DTaP-IPV-Hep B-PRP~T Infanrix®Hexa ) one month third dose primary series . - To assess overall safety group one month dose primary series entire study .</brief_summary>
	<brief_title>Study DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared Infanrix®Hexa Healthy Peruvian Infants</brief_title>
	<detailed_description>The present trial involve two-month old Peruvian infant , randomly assign receive three dos either investigational control vaccine 2 , 4 , 6 month age .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Whooping Cough</mesh_term>
	<mesh_term>Tetanus</mesh_term>
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion Criteria : Two month old infant ( 50 71 day old ) day inclusion , either gender Born full term pregnancy ( ≥ 37 week ) birth weight ≥ 2.5 kg Mother negative Hepatitis B surface Antigen ( HBsAg ) approximately last 30 day pregnancy ( ≥ 36 week amenorrhea ) 30 day post partum Informed consent form sign parent . If one parent ( ) 18 year age , subject 's grandparent ( ) also sign . An independent witness also sign parent ( ) /grandparent ( ) illiterate Able attend schedule visit comply trial procedure Received Bacillus Calmette Guerin ( BCG ) vaccine birth one month life agreement national immunization calendar . Exclusion Criteria : Participation another clinical trial 4 week precede first trial vaccination Planned participation another clinical trial present trial period Known systemic hypersensitivity vaccine component history life threaten reaction trial vaccine vaccine contain substance Congenital acquire immunodeficiency , immunosuppressive therapy longterm ( 2 week ) systemic corticosteroid therapy within last four week Chronic illness stage could interfere trial conduct completion Blood bloodderived product receive since birth Any vaccination 4 week precede first trial vaccination Any plan vaccination trial ( Visit 06 ) , except study vaccine , rotavirus vaccine pneumococcal conjugate vaccine Documented history pertussis , tetanus , diphtheria , poliomyelitis , hepatitis B Haemophilus influenzae type b infection ( ) ( confirm either clinically , serologically , microbiologically ) Previous vaccination pertussis , tetanus , diphtheria , poliomyelitis , hepatitis B Haemophilus influenzae type b infection ( ) Known personal maternal history Human Immunodeficiency Virus , hepatitis B hepatitis C seropositivity Known thrombocytopenia bleed disorder contraindicate intramuscular vaccination History seizure Febrile ( temperature ≥ 38.0°C ) acute illness day inclusion .</criteria>
	<gender>All</gender>
	<minimum_age>50 Days</minimum_age>
	<maximum_age>71 Days</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Diphtheria</keyword>
	<keyword>Tetanus</keyword>
	<keyword>Pertussis</keyword>
	<keyword>whooping cough</keyword>
	<keyword>Haemophilus influenzae type b</keyword>
	<keyword>Hepatitis B</keyword>
	<keyword>Poliomyelitis</keyword>
</DOC>